Merck’s Keytruda Combined with Chemotherapy Receives EC’s Approval for the Treatment of Non-Small Cell Lung Cancer
Shots:
- The EC has granted approval to the company’s Keytruda + Pt-based CT as neoadjuvant treatment followed by Keytruda monotx. as adjuvant treatment, for treating adults with resectable NSCLC at high risk of recurrence
- The approval was supported by the P-III (KEYNOTE-671) study assessing the safety & efficacy of Keytruda + neoadjuvant CT, followed by surgery & Keytruda monotx. as adjuvant treatment vs PBO + neoadjuvant CT, followed by resection & adjuvant PBO for treating resectable stage II, IIIA or IIIB NSCLC patients (n=797)
- The study, at a median follow-up of 29.8mos., demonstrated an improved OS by 28% with mOS not attained vs 52.4mos. & an improved EFS by 41% with mEFS of 47.2mos. vs 18.3 mos.
Ref: Merck | Image: Merck
Related News:- Merck’s Winrevair (sotatercept-csrk) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension (PAH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
